23
July 2024
PureTech Health plc
PureTech Founded Entity
Vedanta Biosciences Expands Leadership Team and Appoints Head of
Commercial
Appointments support ongoing
Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3
RESTORATiVE303 trial of VE303 and planning for commercial stage
activity
PureTech Health plc
(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics
company dedicated to changing the
lives of patients with devastating diseases, noted that its Founded Entity,
Vedanta
Biosciences, a clinical-stage
biopharmaceutical company developing medicines for the treatment of
gastrointestinal diseases, today announced three appointments to
its leadership team. Christof Marré, a seasoned biopharma marketing
leader, joins the company as Senior Vice President and Head of
Commercial. In addition, Steven Shiff, M.D., a pharmaceutical
executive and physician specializing in gastroenterology, has been
appointed as SVP, Clinical Research; and Jack Kyte has been
promoted to SVP, Human Resources.
The full text of the announcement
from Vedanta is as follows:
Vedanta Biosciences Expands
Leadership Team and Appoints Head of Commercial
Appointments support ongoing
Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3
RESTORATiVE303 trial of VE303 and planning for commercial stage
activity
CAMBRIDGE, MA, July 23,
2024 - Vedanta
Biosciences, a clinical-stage
biopharmaceutical company developing medicines for the treatment of
gastrointestinal diseases, today announced three appointments to
its leadership team. Christof Marré, a seasoned biopharma marketing
leader, joins the company as Senior Vice President and Head of
Commercial. In addition, Steven Shiff, M.D., a pharmaceutical
executive and physician specializing in gastroenterology, has been
appointed as SVP, Clinical Research; and Jack Kyte has been
promoted to SVP, Human Resources.
"I am delighted to welcome Christof
and Steve to the team," said Bernat Olle, Ph.D., Co-Founder and
Chief Executive Officer of Vedanta Biosciences. "The expertise that
Christof, Steve, and Jack bring are vital to our next phase of
growth as we execute our ongoing pivotal Phase 3 RESTORATiVE303
trial of VE303 for C.
difficile infection and Phase 2 COLLECTiVE202 trial of VE202
for ulcerative colitis, and establish our commercial
function."
Christof Marré brings almost three
decades of experience as a biopharma marketing leader and
strategist, and most recently served as VP of Marketing &
Pipeline Planning at Alpine Immune Sciences, recently acquired by
Vertex Pharmaceuticals. At Alpine, he established the company's
Commercial function, including building out capabilities in market
research, competitive intelligence, healthcare practitioner
marketing & patient advocacy, and driving indication
prioritization and valuation within the company's Immunology
portfolio. Earlier in his career, Mr. Marré was involved with
multiple successful product launches at both established and
emerging biopharma companies. He holds a Master of Science degree
in Economics from The London School of Economics and Political
Science (LSE).
Steven Shiff, M.D., is a
gastroenterologist and clinical executive with over 20 years of
experience in research and industry R&D. Dr. Shiff was most
recently SVP and Head of Clinical Development at Intercept
Pharmaceuticals, where he oversaw design and implementation of the
company's global clinical development strategy focused on rare and
serious liver diseases, including supporting an NDA filing.
Previously, he served as VP, Clinical Development, and GI
Therapeutic Area Head at Allergan for 14 years, in which capacity
he led global clinical development of the company's GI pipeline and
marketed GI product portfolio. Dr. Shiff spent the first 13 years
of his career as a practicing physician and professor, initially at
The Rockefeller University and later at Rutgers-Robert Wood Johnson
Medical School.
Jack Kyte has served as Vice President and Head of Human Resources at
Vedanta since 2020, following more than a decade of multi-industry
HR experience. Mr. Kyte is responsible for developing and executing
Vedanta's people strategy in alignment with the organization's
current and anticipated future needs and overseeing its human
resources function both internally and with external
partners.
About Vedanta Biosciences
Vedanta
Biosciences is a clinical-stage
biopharmaceutical company developing medicines for the treatment of
gastrointestinal diseases. The company's lead assets are potential
first-in-class oral therapies - VE303, in a Phase 3 registrational
trial for prevention of recurrent C. difficile infection, and VE202, in
a Phase 2 trial for treatment of ulcerative colitis. Vedanta's
pipeline has been built using the company's industry-leading
product engine for the development of therapies based on defined
consortia of bacteria grown from pure clonal cell banks. The
product engine, supported by broad foundational intellectual
property, includes one of the largest libraries of bacteria
isolated from the human microbiome, vast clinical datasets,
proprietary capabilities in consortium design, and end-to-end CGMP
manufacturing capabilities at commercial launch scale.
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to giving life to new classes of
medicine to change the lives of patients with devastating diseases.
The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders that is being
advanced both internally and through its Founded Entities.
PureTech's R&D engine has resulted in the development of 29
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech
or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All
of the underlying programs and platforms that resulted in this
pipeline of therapeutic candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points.
For more information,
visit www.puretechhealth.com or
connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains
statements that are or may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation those related to
the VE303 and VE202 development programs,
development plans and potential benefits to patients and our
future prospects, developments and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2023, filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
UK/EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US
Media
Nichole Bobbyn
+1 774 278 8273
nichole@tenbridgecommunications.com